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a  b  s  t  r  a  c  t
Aims: We  sought to characterize the antibiotic susceptibility of strains of Stenotrophomonas
maltophilia isolated from clinical samples, and the role of Stenotrophomonas maltophilia bioﬁlm
in  antibiotic resistance.
Methods: Fifty-one clinical Stenotrophomonas maltophilia isolates were obtained from patients
with nosocomial infection in the surgical wards and ICUs of six general hospitals in Tianjin,
China. In vitro models of Stenotrophomonas maltophilia bioﬁlms were established and con-
ﬁrmed by scanning electron microscopy and ﬂuorescence microscopy with silver staining.
The  minimal inhibitory concentrations and bioﬁlm inhibitory concentrations of commonly
used antibiotics were determined.
Results: 47 of 51 strains were resistant to three or more antibiotics. 42 of 51 strains formed
Stenotrophomonas maltophilia bioﬁlms in vitro. Stenotrophomonas maltophilia bioﬁlm formation
greatly reduced sensitivity to most tested antibiotics, but not to levoﬂoxacin. However, in the
presence of erythromycin scanning electron microscopy revealed that levoﬂoxacin inhibited
Stenotrophomonas maltophilia bioﬁlm formation. Factorial ANOVA revealed that erythromycin
enhanced susceptibility to levoﬂoxacin, cefoperazone/sulbactam, and piperacillin (p < 0.05),
and an E model revealed that levoﬂoxacin and erythromycin acted synergistically in
bioﬁlms, suggesting speciﬁc use of combined macrolide therapy may represent an effective
treatment for Stenotrophomonas maltophilia infection.
Conclusions: Antibiotics could act synergistically to combat the protection conferred to clini-cal  isolates of Stenotrophomonas maltophilia by bioﬁlms. Macrolide antibiotics may be effective
where used in combination.
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drated through a series of ethanol dilutions, then treated
with isoamyl acetate. The specimen was dried in a vacuum,
then coated with platinum–palladium and analyzed by SEM at
5–10 kV.
Table 1 – Samples from which SMA  was isolated.
Tissues n (%)
Pus 7 (13.7)
Intravascular catheter 7 (13.7)
Postoperative and burn wound 7 (13.7)
Bronchial secretions/lavage 6 (11.8)
Urinary catheter 6 (11.8)
Urine 5 (9.8)
Sputum 4 (7.8)366  b r a z j i n f e c t d 
Introduction
Stenotrophomonas maltophilia (SMA) is an environmental
pathogen and opportunistic Gram-negative bacterium that
can infect immunocompromised patients or otherwise
healthy patients when introduced by contaminated invasive
medical devices.1 Dialysis technology, intubation, artiﬁcial
implants and other widely employed medical materials can
be colonized by bacteria, and SMA  has been observed to
form bacterial bioﬁlms (BBF) on this equipment. In surgi-
cal departments, device-related contamination by potentially
pathogenic bacteria can serve as a source for cross-infection,2
and nosocomial SMA  infections have received increased
attention in recent years.3–11 SMA  bacteremia has been
associated with mortality rates ranging from 14 to 69% in
immunocompromised patients.12–14
Treatment of SMA  infection is complicated by its nat-
ural resistance to many  antimicrobial drugs, including
carbapenems, and the rapid adaptation to the pulmonary
environment.15 SMA  can form BBF on host tissues, dramat-
ically enhancing the resistance of SMA  to therapeutically
important antibiotics including aminoglycosides, ﬂuoro-
quinolones, and tetracycline.16–20 Thus, bioﬁlm formation
represents an important mechanism of bacterial antibi-
otic resistance, and presents unique challenges in surgical
medicine, complicating therapeutic management of such
BBF.21,22
SMA  bioﬁlm formation was previously reported to be
associated with resistance to ceftazidime, cefepime, ticar-
cillin/clavulanic acid, piperacillin/tazobactam, aztreonam,
and gentamicin, but not to ciproﬂoxacin, levoﬂox-
acin, trimethoprim/sulfamethoxazole (TMP/SMX), or
meropenem.23 The ﬂuoroquinolone moxiﬂoxacin was
reported to interfere with SMA  BBF formation24,25; however
antibiotic resistance of clinical isolates has also been widely
reported,26 mostly involving the study of strains isolated from
cystic ﬁbrosis (CF) patients.
In this study we  sought to investigate the antibiotic-
susceptibility of SMA  strains isolated from invasive infec-
tions in non-CF patients. Using a methodology previously
reported27,28 we  established an in vitro model of SMA BBF, and
investigated the antibiotic-susceptibility of SMA  bioﬁlms and
planktonic bacteria. We assessed the capacity of antibiotics,
applied individually and in combination, to reduce growth and
bioﬁlm formation of clinical isolates of SMA, in order to guide
future clinical treatment of these patients.
Materials  and  methods
Antibiotic  susceptibility  of  SMA  isolates
Clinical SMA  strains were obtained from hospitalized patients
with invasive infections that had originated from medical
manipulation in the surgical wards and surgical ICUs of six
general hospitals in Tianjin, China, between 2006 and 2012
(Table 1). The MICs of SMA  to 12 antibiotics commonly used
for Gram-negative bacilli were determined by microbroth dilu-
tion, analyzed according to the American National Clinical 1 6;2  0(4):365–373
and Laboratory Standards Institute (CLSI) guidelines.29 The
following strains were assessed in parallel for quality con-
trol: ATCC27853, ATCC25922 and ATCC25923, preserved in the
Infectious Disease Institute of the Second Hospital of Tianjin
Medical University, China.
In  vitro  model  of  SMA  BBF
Using a methodology previously reported by Ceri27,28 we  estab-
lished an in vitro model of SMA  BBF, in a Mueller–Hinton
broth (MHB)-silica ﬁlm system, as previously described.30,31
Cryopreserved SMA was recovered in sheep blood agar plates
incubated aerobically overnight. A fresh single colony was
transferred to fresh MHB  and incubated for 8 h at 35 ◦C, from
which a 200 L suspension of 0.5 McFarland was prepared
and transferred to a 12-well ﬂat-bottom plate, in which ster-
ile silica ﬁlm (1 cm × 1 cm × 1 mm,  L × W × T) and 1.8 mL  MHB
were co-cultured at 35 ◦C for 12 and 24 h. After washing three
times with 0.9% sodium chloride to remove planktonic bacte-
ria, the BBF on the silica ﬁlms was prepared. The culture
medium was regarded as the negative control. Morphology
was observed by scanning electron microscopy (SEM) and ﬂu-
orescence microscopy (FSM) as described below.
Bioﬁlm  formation  assessed  using  ﬂuorescence  microscopy
with silver  staining
As previously described,32,33 the bioﬁlm was ﬁxed in 2.5% (v/v)
glutaraldehyde in PBS (0.1 M,  pH 7.4) for 24 h, then immersed
in saturated calcium chloride solution for 15 min, and rinsed
with ddH2O between each step. The ﬁlm was immersed in 5%
silver nitrate solution for 15 min, immediately stained with 1%
hydroquinone for 2 min, then rinsed with ddH2O.  The ﬁlm was
ﬁxed in 5% sodium thiosulfate solution for 2 min, then rinsed
in ddH2O and analyzed by FSM.
Bioﬁlm  formation  assessed  using  scanning  electron
microscopy
As previously described,25 the silica bioﬁlm was ﬁxed in 2.5%
(v/v) glutaraldehyde in PBS (0.1 M, pH 7.4) at 4 ◦C for 2 h, ﬁxed
again with 1% osmic acid for 1 h, then rinsed with PBS, dehy-Bile 4 (7.8)
Blood 3 (5.9)
Ascitic ﬂuid 2 (3.9)
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etermination  of  the  MIC
IC  values of the following antibiotics were calculated with a
roth microdilution assay using the twofold dilution method
ccording to the CLSI guidelines34: ciproﬂoxacin (CIP), levo-
oxacin (LEV), piperacillin (PIP), ceftazidime (CAZ), cefopera-
one/sulbactam (SCF), erythromycin (ERY), sulfamethoxazole
SXT), and gentamycin (GM) within the range of CIP was
56–0.125 mg/L, or 512–0.125 mg/L.
etermination  of  the  BIC
fter dilution of the fresh SMA  to 3 × 1010 CFU/mL, 100 L
f the culture was transferred to each well of a ﬂat-bottom
6-well microtiter plate. As previously described,27,28,35,36 BBF
ere formed by immersing the pegs of a modiﬁed polystyrene
icrotiter lid into this plate, which was then incubated at 35 ◦C
or 24 h. Peg lids were removed, rinsed in PBS, then placed on
at-bottom microtiter plates containing antibiotics, and incu-
ated at 35 ◦C. After 24 h peg lids were removed, rinsed three
imes in PBS, then transferred onto ﬂat-bottom microtiter
lates containing 100 L of MHB  per well, and bioﬁlms were
ransferred from pegs to wells by centrifugation at 805 × g for
0 min. The optical density was measured at 650 nm (OD650)
n a microtiter plate colorimeter before and after incubation
t 35 ◦C for 6 h.
Adequate bioﬁlm growth was deﬁned as a mean OD650 dif-
erence (OD650 at 6 h minus  the OD650 at 0 h) of ≥0.05. BICs are
eﬁned as the lowest concentration of antibiotic in which the
D650 was 10% or less of the mean of the positive control well
eadings, representing at least a 1 − log 10 growth difference.
BF  combination  sensitivity  test  by  checkerboard  method
he susceptibility of bioﬁlms to LEV, SCF and PIP alone and in
ombination with ERY was determined by the checkerboard
ethod. Five strains of SMA  (numbered 0020, 0037, 0040, 0088,
256) were selected for the following test. Silica ﬁlms were
ransferred to a 24-well ﬂat-bottom microtiter plate. Then
.0 mL  MHB  was transferred to the well (blank control), 1.8 mL
HB  was transferred to each of the other wells. According to
he MIC  values of LEV, SCF and PIP against each strain, LEV, SCF
nd PIP was added to yield a ﬁnal concentration of 1/2 MIC, 1
IC and 2 MIC, and ERY was added to yield a ﬁnal concentra-
ion of 1/16 MIC  and 1/4 MIC. The plate was incubated at 35 ◦C
or 24 h, then after washing with sterile physiological saline,
he silica ﬁlms were ultrasonicated at 60 W for at 15 min.
he colony concentration was calculated from the OD650 by
he ATCC27853 standard curve (Y = 1.26514 × 10 − 8X + 0.48028,
ith a linear range between 1.5 × 108 and 9.6 × 103 CFU/mL,
 < 0.01). The density of colonies on the silica ﬁlm was recorded
rom three wells in parallel.
tatistical  analysis
FU per centimeter was indicated by mean ± standard devi-
tion, and the interaction of combined testing was analyzed
y factorial experiment design ANOVA. The impact of antibi-
tics on bioﬁlm growth was calculated using an E model
s based on the Bliss independence theory, described by6;2 0(4):365–373 367
the equation Ii = (IA + IB) − (IA × IB), where Ii is the predicted
growth inhibition caused by the theoretical combination of
drugs A and B, and IA and IB represent the growth inhibition
caused by each drug individually. Since I = 1 − E, where E rep-
resents growth inhibition, the following equation is derived:
Ei = EA × EB. Ei represented the predicted growth inhibition
of the theoretical non-interactive combination of the drugs
A and B, and EA and EB represent the growth inhibition
caused by each drug individually. Interaction was described
as the difference (E) between the predicted and measured
growth inhibition (E = Epredicted − Emeasured). Statistically sig-
niﬁcant interactions of <100% were considered weak, those of
100–200% were considered moderate, and those >200% were
considered strong.
Results
Antibiotic  susceptibility  of  clinical  SMA  isolates
The antibiotic susceptibility of SMA isolates was assessed and
in total, 47 (92.1%) of isolated strains were resistant to three
or more  antibiotics. The majority of tested strains were resis-
tant to cefotaxime (94.1%) amikacin (90.2%) cefritaxone (88.2%)
GM (82.4%) and CAZ (60.8%), and almost half of all tested
strains were resistant to cefoperazone (49.0%), PIP (45.1%) and
cefepime (45.1%).
Clinical  SMA  isolates  form  BBF
The capacity of clinical isolates of SMA  strain 0314 to form
bioﬁlms on the surface of the silica ﬁlms incubated in MHB
was assessed by ﬂuorescent microscopy. Mature bioﬁlms were
formed by 42 of the 51 SMA isolates (82.35%). After 24 h, sil-
ver staining revealed mature bioﬁlm to be composed of black
irregular sheets, scattered dots and black cottony membranes,
and ﬁne rod-shaped bacteria were observed at the borders
(Fig. 1). No black aggregation was observed on the surface of
silica ﬁlm cultured in MHB in the absence of SMA. These ﬁnd-
ings were conﬁrmed by SEM (Fig. 2). Bioﬁlm ultrastructure was
observed after 12 h (Fig. 2C), and mature bioﬁlm was observed
at 24 h (Fig. 2A and B). SMA  was observed to be clustered on
the surface of the bioﬁlm, and SMA  was mostly short rods
of about 1.5 m × 1.0 m,  partially or entirely encompassed by
the extracellular matrix (Fig. 2A and C). Fine bacilli alternated
cross lots of extracellular mucus ﬁlaments, some cells were
visible in split phase or undergoing apoptosis, and the bac-
terial community present on the bioﬁlm was heterogeneous
(Fig. 2B). No bacteria were observed on the surface of silica
ﬁlm cultured in MHB in the absence of SMA  (Fig. 2D).
BBF  formation  enhances  SMA  antibiotic  resistance
The effect of antibiotic agents on bioﬁlm formation was ana-
lyzed by comparing MICs with BIC. The formation of bioﬁlms
enhanced the resistance of some strains to all tested antibi-
otics aside from GM and ERY, to which all the tested strains
were resistant even in the absence of bioﬁlm, and LEV (Table 2).
After bioﬁlm formation, 21 (50.0%) tested isolates were resis-


























Table 2 – The Susceptibility of 42 SMA  strains and their bioﬁlms to 8 antibiotic agents.














Levoﬂoxacin R ≥ 8 S ≤ 2 4 (9.52) 3 (7.14) 35 (83.33) 0.125–32 21 (50.00) 6 (14.29) 15 (35.71) 0.125–512
Ciproﬂoxacin R ≥ 4 S ≤ 1 16 (38.10) 17 (40.48) 9 (21.43) 0.5–128 32 (76.19) 9 (21.43) 1 (2.38) 0.5–1024
Ceftazidime R ≥ 32 S ≤ 8 26 (61.90) 10 (23.81) 6 (14.29) 0.5–512 32 (76.19) 2 (4.76) 8 (19.05) 0.5–1024
Cefoperazone/sulbactam R ≥ 64 S ≤ 16 16 (38.10) 13 (30.95) 13 (30.95) 0.5–512 32 (76.19) 1 (2.38) 9 (21.43) 0.5–1024
Piperacillin R ≥ 128 S ≤ 64 18 (42.86) 0 (0.00) 24 (57.14) 0.5–512 33 (78.57) 0 (0.00) 9 (21.43) 2–4096
Erythromycin R ≥ 8 S ≤ 0.5 42 (100.00) 0 (0.00) 0 (0.00) 0.5–512 42 (100.00) 0 (0.00) 0 (0.00) 0.5–1024
Sulfamethoxazole R ≥ 152 S  ≤ 38 10 (23.81) 8 (19.05) 24 (57.14) 2.375–608 33 (78.57) 3 (7.14) 6 (14.29) 2.38–2432
Gentamycin R ≥ 8 S ≤ 4 41 (97.62) 0 (0.00) 1 (2.38) 0.5–512 42 (100.00) 0 (0.00) 0 (0.00) 0.5–1024
R, resistant; I, intermediate susceptibility; S, susceptible.
Susceptibility of the bacteria in BBF was estimated from criteria set for planktonic cells, because of no identiﬁed criteria that were especially applicable to BBF. MICs, were determined by the microbroth
two-fold dilution method. BICs, refer to a previously developed technique (Hill et al.,35 Moskowitz et al.,36 Olson et al.,27 Tomlin et al.28).  The results represent all 42 isolates that could form mature
bioﬁlms in vitro in all 51 clinical strains.
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Fig. 1 – In vitro SMA  BBF formation was visualized by ﬂuorescence microscopy (×200). After 24 h SMA  strain 0314 cultured in
MHB formed BBF on silica ﬁlm. Black irregular sheets, scattered black dots, and cotton-like membranes were observed, and
ﬁne rod-shaped bacteria were  observed at the borders (A). No black aggregation was observed on the surface of silica ﬁlm
cultured in MHB  in the absence of SMA  (B).
Table 3 – Comparison of antibiotic susceptibility of the planktonic bacteria and bioﬁlms of 42 SMA  strains.
Antibiotic agent MIC (g/ml) BIC (g/ml)
MIC50a MIC90b Range BIC50c BIC90d Range
Levoﬂoxacin 0.25 2 0.125–32 4 64 0.125–512
Ciproﬂoxacin 2 8 0.5–128 8 256 0.5–1024
Ceftazidime 32 128 0.5–512 128 512 0.5–1024
Cefoperazone/sulbactam 16 64 0.5–512 128 1024 0.5–1024
Piperacillin 64 512 0.5–1024 256 >1024 0.5–1024
Erythromycin 32 256 0.5–1024 128 >1024 0.5–1024
Sulfamethoxazole 19 76 2.375–608 304 >2432 2.375–2432
Gentamycin 32 512 0.5–1024 256 >1024 0.5–1024












Cb MIC inhibited 90% of the isolates tested.
c BIC inhibited 50% of the isolates tested.
d BIC inhibited 90% of the isolates tested.
o CAZ, 32 (76.19%) to SCF, and 32 (76.19%) to CIP. The average
IC90 was also much higher than the MIC90 (Table 3).
apacity  of  ERY  to  overcome  BBF-mediated  antibiotic
esistancehe effects of combining ERY with other antibiotics was inves-
igated in ﬁve SMA  isolates which were determined to have
ig. 2 – Ultrastructure of in vitro SMA  BBF visualized by scanning
314 cultured in MHB  on silica ﬁlm was observed (C), and was m
lusters of proliferating bacteria (A, C). SMA  was mostly short rod
ncompassed by the extracellular matrix. A large number of ﬁne
o bacteria were  observed on the surface of silica ﬁlm cultured in
, D ×5000; Bar = 20 m.moderate susceptibility to LEV, SCF and PIP. The MIC  of LEV
in the chosen strains (0020, 0037, 0040, 0080 and 0256) was
between 0.5 and 64 mg/L, the MIC of SCF was between 8 and
32 mg/L and the MIC of PIP was between 2 and 64 mg/L. Addi-
tion of ERY did not signiﬁcantly enhance the efﬁcacy of SCF
(p = 0.06), but did signiﬁcantly enhance LEV and PIP efﬁcacy
(all p < 0.05). Factorial ANOVA analysis revealed that the efﬁ-
cacy of SCF, LEV, and PIP was signiﬁcantly improved in the
 electron microscopy. After 12 h the bioﬁlm of SMA  strain
ature at 24 h (A, B). SMA  bioﬁlm ultrastructure included
s of about 1.5 m × 1.0 m,  partially or entirely
 bacilli alternated across numerous ﬁlamentous strands (B).
 MHB  in the absence of SMA  (D). B ×20,000, Bar = 50 m; A,
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Table 4 – Effect of antibiotics alone and in combination on the SMA  bioﬁlms.
Antibiotic agent Colony density (104 CFU/cm2)a
– ½ MIC 1 MIC 2 MIC
SCF No  ERY 149.6 ± 3.8 150.80 ± 3.7 153.40 ± 4.9 152.20 ± 4.8
ERY 1/16 MIC 149.2 ± 5.0 147.60 ± 6.3 140.00 ± 3.4 132.80 ± 4.7
ERY ¼ MIC 150.2 ± 4.0 141.00 ± 5.4 132.20 ± 3.3 130.00 ± 4.5
PIP No ERY 148.4 ± 5.6 146.20 ± 3.4 153.20 ± 3.7 148.20 ± 5.5
ERY 1/16MIC 147.4 ± 4.8 144.60 ± 5.5 143.80 ± 5.4 133.20 ± 5.2
ERY 1/4MIC 150.6 ± 5.8 143.40 ± 5.9 140.40 ± 4.6 130.80 ± 3.7
LEV No ERY 153.0 ± 4.1 131.80 ± 4.5 117.40 ± 5.1 108.20 ± 4.9
ERY 1/16MIC 149.2 ± 5.4 120.40 ± 3.6 89.80 ± 4.4 80.60 ± 3.9
ERY 1/4MIC 151.2 ± 4.3 96.00 ± 7.5 75.60 ± 5.8 66.20 ± 5.5
LEV, levoﬂoxacin; PIP, piperacillin; SCF, cefoperazone/sulbactam; ERY, erythromycin.
Combination tests all revealed a statistical interaction by factorial experiment design and ANOVA, of SCF with ERY (F = 8.460, p = 0.000), LEV with
ively.ERY (F = 20.825, p = 0.000), and PIP with ERY (F = 4.506, p = 0.00) respect
a Results were expressed as the mean of ﬁve SMA isolates.
presence of ERY (F = 8.460, p = 0.000; F = 20.825, p = 0.000; and
F = 4.506, p = 0.001, respectively; Table 4, and one-way ANOVA,
p < 0.05). The synergy of antibiotics was assessed by the E
model, and the combination of ERY and LEV was found to
have a synergistic effect against four of the ﬁve strains tested
(Table 5).
SMA  strain 0020 bioﬁlm formation was also assessed
in the presence of SCF, LEV, PIP and/or ERY (Fig. 3). We
observed that LEV damaged BBF in the presence or absence
of ERY (Fig. 3A and B), but the combination of ERY with LEV
reduced the number of bacteria anchored to the BBF, thinned
the polysaccharide matrix and altered bacterial morphology.
Some spherical, irregularly shaped, or cracked bacteria were
observed. In the absence of antibiotics, the BBF was mature
and bacterial cells were packaged in a lot of sticky polysac-
charide matrix. Bacterial growth was strong and some bacteria
were observed to be in the division phase (Fig. 3C). Neither PIP
nor SCF, in the presence or absence of ERY, altered the state of
the bacteria or bioﬁlm (Fig. 3D).
Discussion
Treatment of nosocomial SMA  infections is complicated by
high rates of antibiotic resistance. Although pharmacokine-
tics and drug penetration inﬂuence the clinical efﬁcacy of
antibiotics against planktonic bacterial, resistance can be
characterized in in vitro susceptibility tests. In this study
we sought to investigate the antibiotic-susceptibility of SMA
strains isolated from invasive infections in non-CF patients.
We established an in vitro model of SMA  BBF, and investigated
the antibiotic-susceptibility of SMA  bioﬁlms and planktonic
bacteria. Fifty-one clinical isolates of SMA  were taken from
patients infected with SMA  through medical manipulation
and/or immunosuppressive therapy in the surgical depart-
ments of Tianjin hospitals.In our sample the vast majority of isolated strains (92.16%)
were resistant to three or more  antibiotics. The highest rate
of resistance was to cefotaxime (94.1%) and the lowest (only
13.7%) was to LEV. The intrinsic or acquired resistance of SMAto antibiotics has been previously reported, and drastically
reduces the antibiotic options available for treatment.22
BBF formation was also reported to enhance antibiotic
resistance. Bacterial adhesion involves development of pili,
changes in cell surface and hydrophobicity, and is crucial
to BBF formation,37,38 but the mechanism of BBF formation
varies by attachment substrate.38 We selected silicon ﬁlm
as an attachment matrix because of its superior resistance
to corrosion, chemical stability and non-tackiness. A major-
ity of SMA strains included in our study formed bioﬁlms in
vitro, and mature bioﬁlms were observed within 24 h, sug-
gesting that transmission of these clinical isolates may have
been facilitated by development of bioﬁlms on clinical tools.
BBF structure was identiﬁed by silver staining character-
ized by SEM ultrastructure analysis. The extracellular matrix
around the bacteria appeared to be made up of secreted
exopolysaccharide. BBF formation was previously reported to
be associated with S. maltophilia ﬁmbriae 1 (SMF-1), which is
composed of ﬁmbrin subunits and shares signiﬁcant similarity
with the N-terminal amino acid sequences of several ﬁmbrial
adhesins of pathogenic Escherichia coli strains and the Cup A
ﬁmbriae in Pseudomonas aeruginosa.39
In our sample, all clinical isolates were more  resistant
to antibiotics in the BBF than in planktonic state. BBF
have been previously reported to confer antibiotic resis-
tance of up to 1000-fold,16–20 and thus BBF formation is
thought to be an important mechanism of antibiotic resis-
tance by SMA. The BBF constitute a positively charged
polysaccharide matrix barrier to antibiotics with a nega-
tive charge, such as aminoglycosides.21 The extracellular
polysaccharide matrix can also absorb high levels of extra-
cellular enzymes, such as -lactamase. We found that most
isolates were resistant to -lactams, including third and
fourth generation cephalosporins, although resistance to cef-
operazone/sulbactam was lower. SMA strains wrapped in
extracellular polysaccharide matrices are less able to obtain
molecular oxygen and nutrients, and to eliminate metabo-
lites, which can cause bacterial dormancy or retarded growth
rates, and local metabolite accumulation.22 Thus, in this study,
antimicrobial agents that target bacterial growth, such as -


























Table 5 – In vitro interactions of ERY in combination with SCF, PIP, and LEV against BBF, and as indicated by the E  model.





SCF PIP LEV SCF PIP LEV SCF PIP LEV SCF PIP LEV
0020 8.97 (−0.64 to 16.62) 9.43 (2.05 to 15.78) 17.38 (−0.85 to 29.65) 54.44 (5) 56.55 (6) 105.13 (5) −0.64 (1) 0 (0) −0.85 (1) NI NI SYN
0037 15.37 (4.13 to 22.26) 4.18 (−2.04 to 8.96) 27.29 (12.17 to 38.71) 92.32 (6) 27.09 (5) 163.72 (6) 0 (0) −2.04 (1) 0 (0) NI NI SYN
0040 10.05 (1.34 to 18.15) 3.54 (−10.83 to 15.75) 19.33 (8.55 to 28.94) 60.29 (6) 34.88 (4) 115.96 (6) 0 (0) −13.62 (2) 0 (0) NI NI SYN
0088 7.64 (−0.68 to 13.68) 7.10 (2.04 to 13.33) 12.77 (0.10 to 20.21) 46.10 (6) 42.57 (60 76.63 (6) 0 (0) 0 (0) 0 (0) NI NI NI
0256 9.01 (5.39 to 12.84) 12.57 (8.06 to 17.99) 17.37 (6.12 to 25.99) 54.06 (6) 75.44 (6) 104.21 (6) 0 (0) 0 (0) 0 (0) NI NI SYN
NI, no interaction; SYN, synergism; ANT, antagonism; n, number of interactions.
a and b were the sums of the percentages of all statistically signiﬁcant synergistic and antagonistic interactions.
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Fig. 3 – Impact of antibiotic agents on ultrastructure of in vitro BBF visualized by scanning electron microscopy. SMA strain
0020 BBF formed a complete mature structure in which the bacterial were packaged with dense matrix (C). In the presence
of erythromycin (B) or erythromycin and levoﬂoxacin (A) the BBF matrix became thin, fewer adhered bacteria were observed
and some exhibited spherical or irregular form. The black arrow indicates a bacterial cell undergoing division phase. In the
presence of erythromycin and piperacillin the BBF remained similar to that seen in the blank control (D). D ×20,000;
rBar = 100 m;  A, B, C ×5000; Bar = 50 m.
to local metabolite accumulation, the microenvironment of
bacteria living deep in tissues is acidic, which inactivates most
of the therapeutic drugs that optimally act in neutral condi-
tions.
SMA  gene expression proﬁles have been reported to change
signiﬁcantly on BBF formation, presenting a range of mecha-
nisms for development of antibiotic resistance.40
Development of BBF also enables evasion of the host
immune response. The glycocalyx shell protects bacteria
from phagocytosis and secreted quorum-sensing factor N-(3-
oxododecanoyl)-l-homoserine lactone (HSL) and C4-HSL can
inhibit leukocyte proliferation and cytokine secretion.41 Pro-
tection from the host immune response provides a protected
niche in which SMA  can evolve resistance to previously effec-
tive antimicrobials.
In this study, formation of bioﬁlm conferred resistance
to all tested antimicrobials aside from LEV, according to
CLSI break points. LEV alone inhibits mature BBF in a
concentration-dependent manner, which indicates that the
in vivo maximum permissible dosage for BBF should be inves-
tigated. Complete elimination of bioﬁlm infection remains
challenging, but inhibiting bacterial adherence or destroy-
ing the matrix may prove useful tactics, in combination with
activated host immunity. Macrolides have been reported to
assist other antibiotics in bactericidal effects on P. aeruginosa
BBF, by inhibiting synthesis of GDP-mannose dehydrogenase,
the main component of bioﬁlms.42,43 Moreover, macrolides
can inhibit neutrophil accumulation, and promote improved
CD4+/CD8+ T cell ratios.44,45 In this study ERY, a 14-membered
ring macrolide, acted synergistically with LEV, SCF and PIP,
even where SMA  strains were resistant to ERY alone. ERY
markedly enhanced efﬁcacy of LEV and was observed to
reduce bacterial adhesion to bioﬁlms and undermined bioﬁlm
architecture. We  selected LEV, SCF and PIP to test in combina-
tion with ERY based on their BIC value, but other combinations
of antimicrobials may also show clinical effectiveness. There-
fore, further combinations of antimicrobials should be tested
in future.In summary, we  found that antibiotics could act synergis-
tically to combat the protection conferred to clinical isolates
of SMA  by BBF. Our ﬁndings suggest that macrolide antibioticsmay be effective where used in combination. However further
speciﬁc in vivo studies will be required to conﬁrm whether this
approach can treat nosocomial SMA infection in the clinic.
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